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Objective: To evaluate the effects of weight change on asthma control, asthma-related quality
of life, number of steroid bursts, and exacerbation of asthma symptoms in a population of
adult patients with severe or difficult-to-treat asthma who participated in The Epidemiology
and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study.
Methods: We categorized 2396 TENOR patients 18 years into three groups (5 lb loss, stable,
5 lb gain), based on a 5 lb (2.27 kg) difference between baseline and 12-month follow-up
weight. We used proportional odds and logistic regression models to evaluate the effect of
weight change on Asthma Therapy Assessment Questionnaire (ATAQ) and Asthma Quality of
Life Questionnaire (AQLQ) scores, exacerbations, and steroid bursts at the 12-month follow-up.
Results: Asthma patients who gained 5 lb (2.27 kg) during the 12-month interval between
baseline and follow-up reported poorer asthma control (adjusted odds ratio [OR]: 1.22; 95%
confidence interval [CI]: 1.01e1.49; pZ 0.04), worse quality of life (least square means:
0.18; 95% CI: 0.30 to 0.06; p Z 0.003), and a greater number of steroid bursts
(OR: 1.31; CI: 1.04e1.66; pZ 0.02) than patients who maintained their baseline weight or lost
5 lb (2.27 kg).entech, Inc. and Novartis Pharmaceuticals Corp.
1 408 730 2503.
gene.com (T. Haselkorn).
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Weight change and asthma-related health outcomes 275Conclusion: Increased weight is associated with worse asthma-related health outcomes.
Strategies to prevent weight gain could help patients achieve better asthma control and
improve asthma-related quality of life.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic condition affecting millions of indi-
viduals worldwide and has a substantial incidence rate
that continues to rise.1 Although patients with severe or
difficult-to-treat asthma represent a small portion of
asthma patients, they account for much of the morbidity,
mortality, and costs associated with the disease.2
Symptom control is the goal of asthma treatment;
however, current levels of control fall short of interna-
tional guidelines.3
Body mass index (BMI) is positively correlated with
asthma incidence and severity.1,4,5 Although a handful of
studies have reported the beneficial effects of weight loss
on asthma symptoms,6e9 none have evaluated the effects
of weight change on asthma control. To better characterize
the relationship between body weight/BMI and asthma
control, and the variables that influence it, we analyzed
characteristics of severe or difficult-to-treat asthma
patients who participated in The Epidemiology and Natural
History of Asthma: Outcomes and Treatment Regimens
(TENOR)2 study. Our primary objective was to evaluate the
effects of weight change on asthma control, asthma-
related quality of life (QoL), number of steroid bursts, and
asthma exacerbations.Original TENOR cohort
n=4,756
Ages ≤18
n=1,268
Missing 12 month visit
n=907
Missing baseline height or weight
n=14
Missing 12 month weight
n=48
Missing ATAQ
n=123
Subjects included in analysis
n=2,396
n=3,488
Reason for Exclusion
n=2,581
n=2,567
n=2,519
ATAQ = Asthma Therapy Assessment Questionnaire. 
Figure 1 Inclusion and exclusion criteria for current analysis.Materials and methods
We analyzed baseline and 12-month follow-up data of
TENOR patients 18 years. Patients were categorized into
three groups (5 lb loss, stable, or 5 lb gain), based on
a 5 lb (2.27 kg) difference between baseline and 12-
month follow-up weight. Five pounds was chosen for
assessing weight gain/loss because changes of that magni-
tude were sufficiently common in our cohort to allow for
comparisons, but not likely to be visit-to-visit measurement
error. In addition, 5 lb was deemed to be a low, yet
reasonable and actionable cutpoint that physicians could
easily communicate to their patients.
Of the 3488 TENOR patients considered for this analysis,
those excluded did not attend a 12-month follow-up visit
(nZ 907), have baseline height and weight (nZ 14) or 12-
month weight (nZ 48) available, and/or did not complete
the Asthma Therapy Assessment Questionnaire (ATAQ)10
(nZ 123) (Fig. 1). There were some statistical differences
between included and excluded patients; however, those
included in the present analysis did not differ from the
overall 18-year-old cohort with respect to primary anal-
ysis variables (e.g. mean age 50 vs. 49 years; baseline BMI
30.4 vs. 30.4; control problems 1.9 vs. 1.8; percent female
72 vs. 71).Study population
TENOR methodology and baseline population characteris-
tics have been described previously.2 Briefly, TENOR was
a multicenter, observational study of 4756 patients
6 years with severe or difficult-to-treat asthma, living in
diverse geographical areas of the United States. Patients
with mild or moderate asthma were eligible for enrollment
if their pulmonologists/allergists considered their asthma
difficult-to-treat. At enrollment, patients had been
receiving care from their respective asthma specialists for
at least 1 year and were frequent users of health care and/
or asthma medication. Heavy smokers (30 pack-years) and
patients diagnosed with cystic fibrosis were excluded.
There was no experimental intervention, and patients
continued to receive medication and treatment prescribed
by their asthma specialists. All participants provided
written informed consent. The TENOR design and protocol
were approved by a central institutional review board and,
when necessary, by the institutional review board at each
site.
Data collection
Data were collected at baseline and semi-annually via study
coordinator-administered interviews. During those visits,
276 T. Haselkorn et al.patients also completed several self-administered ques-
tionnaires and reported the previous 3 months’ asthma-
related health care utilization.
Information about region and mean income were esti-
mated using patients’ Zip Code Tabulation Area from the
2000 US Census.11 Geographic location was further classi-
fied as ‘‘urban’’ or ‘‘rural,’’ according to zip code, as
defined in the Rural Urban Commuting Area classification
system.12
Asthma severity
Pulmonologists/allergists subjectively categorized each
patient’s asthma as mild, moderate, or severe. Asthma was
also categorized according to two classification schemes:
the National Asthma Education and Prevention Program
(NAEPP) Expert Panel Report-213 and the Global Initiative
for Asthma (GINA)14 guidelines.
Asthma control and asthma-related quality of life
Asthma control was assessed by the ATAQ control index,
which ranges from zero to four problems (0Z well-
controlled; 1e2Z not well-controlled; 3e4Z poorly
controlled). Patients also completed the Mini-Asthma
Quality of Life Questionnaire (MiniAQLQ).15 MiniAQLQ items
are scored from one to seven; higher scores represent
better QoL. The minimal important difference (MID) for the
AQLQ has been estimated to be 0.5.16
WPAI-asthma
An asthma-specific adaptation of the allergy-specific Work
Productivity and Activity Impairment (WPAI-AS)17 instru-
ment was used to assess work productivity and daily activity
(range 0%e100% impairment). The performance charac-
teristics of the WPAI-AS support its validity as a measure of
asthma-related impairment in patients with severe or
difficult-to-treat asthma.18
Spirometry
Spirometry was performed according to American Thoracic
Society guidelines19 with a certified device, calibrated
daily. Predicted spirometry values were adjusted for race,
according to Hankinson reference values.20
Skin test and IgE measurement
Skin test results were self-reported by patients. Total serum
IgE concentration (IU/mL) was measured at baseline, using
any commercially available assay that met 510 (K) Food and
Drug Administration approval and was calibrated to the
World Health Organization’s Second International Reference
Preparation for Human Serum IgE (WHO IRP 75/502).
Statistical analysis
Descriptive analysis
Body weight was compared at baseline and 12-month
follow-up for each patient. Patients were categorized intothree groups (5 lb loss, stable, or 5 lb gain), based on
a 5 lb (2.27 kg) change in weight between baseline and
follow-up. A core set of variables was summarized for each
group. Group comparisons were made using chi-square and
F-tests for categorical and continuous variables, respec-
tively. Although the analyses were intended for descriptive
purposes, we used p values to identify potential
confounders in our primary analyses.
Primary analyses
We modeled ATAQ at the 12-month follow-up, using
a proportional odds model. Weight group was the primary
predictor variable and was forced into the model, as were
variables that are known to be associated with weight and
poor asthma outcomes, including BMI at baseline, age, sex,
and race.21,22 Additional demographic (i.e. geographic
region, urban/rural, education, employment status, income,
health care provider) and clinical (i.e. GINA severity, race-
adjusted percent predicted forced expiratory volume in 1 s
[FEV1], serum IgE, skin test, history of atopic dermatitis and
allergic rhinitis, bronchitis, chronic obstructive pulmonary
disease, duration of asthma, oral steroid use, treatment
setting) data were included in the model in a stepwise
fashion if they were independently predictive of the
outcome after considering the variables already included in
the model. Unlike the variables that were forced into the
model, these potential covariates were only included if they
met the entry threshold of alphaZ 0.05. For categorical
variables with n categories, the entry criteria were based on
the n  1 degree of freedom test evaluating the statistical
significance of the variable as a whole, not the individual
categories from which the variable is comprised.
We modeled MiniAQLQ at the 12-month follow-up in
a similar way, using a linear regression model. Logistic
regression was used to analyze asthma exacerbations
(emergency room [ER] visit or hospitalization) and steroid
bursts (short-term increase in corticosteroid therapy to
treat an exacerbation of symptoms).Missing data
Patients for whom individual predictor variable information
was not available were excluded from the descriptive
analyses pertaining to those variables. All analyses were
performed with SAS software (v.9.1 or higher; SAS Institute
Inc., Cary, NC).Results
Patient demographics
Of the TENOR patients, 2396 (1730 women, 666 men) met
the inclusion criteria. Of those, 652 were classified in the
5 lb (2.27 kg) gain group (6e75 lb (2.7e34.1 kg) gained),
557 in the 5 lb (2.27 kg) loss group (6e65 lb (2.7e
29.5 kg) lost), and 1187 in the stable group (<5 lb
(<2.27 kg) gained or lost). The groups differed significantly
in baseline weight and BMI, age, race, employment status,
geographic region, estimated income, and control (Table 1).
Among the clinical measures evaluated, mean actual post-
Table 1 Baseline demographics of the 2396 TENOR patients included in the analysis.
Variables Weight change at 12-month follow-up p value
5 lb (2.27 kg) loss Stable 5 lb (2.27 kg) gain
Total patients, n (%) 557 (23.2) 1187 (49.5) 652 (27.2)
Mean age, years  SD 49.7  14.9 51.3  14.7 48.0  13.5 <0.0001
Gender, n (%)
Female 415 (74.5) 837 (70.5) 478 (73.3) NS
Male 142 (25.5) 350 (29.5) 174 (26.7)
Race, n (%)
White 455 (81.7) 993 (83.7) 523 (80.2) 0.020
Black 71 (12.7) 103 (8.7) 81 (12.4)
Other 31 (5.6) 91 (7.7) 48 (7.4)
Education, n (%)
High school or less 151 (27.1) 337 (28.4) 181 (27.8) NS
Some college/trade school 197 (34.4) 395 (33.3) 212 (32.5)
College graduate/advance degree 209 (37.5) 455 (38.3) 259 (39.7)
Employment status, n (%)
Full-time *244 (43.8) 541 (45.6) 337 (51.7) <0.0001
Part-time 60 (10.8) 164 (13.8) 77 (11.8)
Student 12 (2.2) 21 (1.8) 17 (2.6)
Homemaker 50 (9.0) 94 (7.9) 40 (6.1)
Retired 100 (18.0) 245 (20.6) 84 (12.9)
Disabled 68 (12.2) 83 (7.0) 71 (10.9)
Unemployed 23 (4.1) 39 (3.3) 26 (4.0)
Geographic region, n (%)
Northeast *116 (21.0) *272 (23.1) *117 (18.1) 0.007
Midwest 112 (20.3) 184 (15.6) 119 (18.4)
South 148 (26.8) 304 (25.9) 206 (31.8)
West 176 (31.9) 416 (35.4) 206 (31.8)
Urban/rural, n (%)
Urban core *444 (80.6) *914 (77.9) *491 (77.0) NS
Suburban 47 (8.5) 124 (10.6) 74 (11.6)
Large town 25 (4.5) 62 (5.3) 35 (5.5)
Small town/isolated
Rural 35 (6.4) 74 (6.3) 38 (6.0)
Mean annual estimated income (USD)  SD 56,639  20,212 58,813  22,754 55,458  19,500 0.004
Healthcare provider, n (%)
Commercial/PPO 243 (43.6) 524 (44.1) 285 (43.7) NS
HMO 138 (24.8) 337 (28.4) 190 (29.1)
Medicaid 31 (5.6) 46 (3.9) 38 (5.8)
Medicare 103 (18.5) 212 (17.9) 92 (14.1)
Other 42 (7.5) 68 (5.7) 47 (7.2)
*Some patient data missing for these variables. HMOZ health maintenance organization; NSZ not significant; PPOZ preferred
provider organization; TENORZ The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens; USDZ United
States dollar.
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between the three groups (p < 0.05); however, the differ-
ences were not clinically meaningful (Table 2). Baseline
medication use was similar between the groups, except for
oral steroid use (pZ 0.048). The histograms in Fig. 2 show
that the distribution of patient weight was similar to that ofBMI at baseline and at 12-month follow-up, and weight
change and BMI percent change were normally distributed
at 12-month follow-up. Approximately 741 (39%) of the
patients fell into the overweight category (i.e. BMI 25e
<30), and at least 1052 (44%) met the criteria for obesity
(i.e. BMI 30).23
Table 2 Baseline clinical characteristics of the 2396 TENOR patients included in the analysis.
Variables 5 lb (2.27 kg) loss Stable 5 lb (2.27 kg) gain p value
Total patients, n (%) 557 (23.2) 1187 (49.5) 652 (27.2)
Mean BMI (kg/m2)  SD 32.5  8.0 29.4  7.2 30.6  7.3 <0.0001
Mean body weight (lb)  SD 197.9  51.0 177.2  45.2 186.0  46.3 <0.0001
Mean post-bronchodilator % predicted FEV1  SD 78.6  22.1 78.0  22.9 80.3  22.4 NS
Mean post-bronchodilator
actual FEV1/FVC (%)  SD
72.7  11.9 70.8  12.2 72.1  11.9 0.007
Mean race-adjusted
post-bronchodilator % predicted FEV1  SD
76.6  20.6 75.6  21.2 77.8  20.8 NS
Treating specialist, n (%)
Pulmonologist *161 (29.9) *310 (26.9) *156 (24.8) NS
Allergist 377 (70.1) 842 (73.1) 473 (75.2)
Physician-assessed severity, n (%)
Mild *9 (1.6) 34 (2.9) 16 (2.5) NS
Moderate 260 (46.8) 561 (47.3) 300 (46.0)
Severe 287 (51.6) 592 (49.9) 336 (51.5)
NAEPP severity, n (%)
Mild 119 (21.5) 294 (25.0) 170 (26.3) NS
Moderate 155 (28.0) 344 (29.3) 182 (28.1)
Severe 279 (50.5) 536 (45.7) 295 (45.6)
GINA severity, n (%)
Mild *19 (3.5) *28 (2.4) *12 (1.9) NS
Moderate 205 (37.3) 488 (41.8) 253 (39.2)
Severe 325 (59.2) 652 (55.8) 381 (59.0)
Oral steroid use, n (%) 135 (24.3) 237 (20.0) 123 (18.9) 0.048
ATAQ control problems, n (%)
0 89 (16.3) 222 (19.0) 101 (15.7) 0.003
1 103 (18.9) 256 (21.9) 115 (17.8)
2 162 (29.7) 377 (32.2) 208 (32.2)
3þ 192 (35.2) 315 (26.9) 221 (34.3)
Skin test result, n (%)
Positive *445 (81.1) *970 (82.0) *542 (83.5) NS
Negative 32 (5.8) 65 (5.5) 34 (5.2)
Never tested 72 (13.1) 148 (12.5) 73 (11.2)
COPD, n (%)
Yes 50 (9.0) 108 (9.1) 42 (6.4) NS
No 507 (91.0) 1079 (90.9) 610 (93.6)
Bronchitis, n (%)
Yes 209 (37.5) 428 (36.1) *225 (34.6) NS
No 348 (62.5) 759 (63.9) 426 (65.4)
History of allergic rhinitis, n (%)
Yes 398 (71.5) 848 (71.4) 481 (73.8) NS
No 41 (7.4) 87 (7.3) 39 (6.0)
Not sure 118 (21.2) 252 (21.2) 132 (20.2)
History of atopic dermatitis, n (%)
Yes 68 (12.2) 167 (14.1) *92 (14.1) NS
No 360 (64.6) 781 (65.8) 433 (66.5)
Not sure 129 (23.2) 239 (20.1) 126 (19.4)
(continued on next page)
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Table 2 (continued )
Variables 5 lb (2.27 kg) loss Stable 5 lb (2.27 kg) gain p value
IgE IU/mL
Geometric mean 81.6 87.2 76.7 NS
95% CI 80.0e93.9 79.1e96.0 67.8e86.8
Median 94.5 89.0 78.0
Range 1e6,859 1e15,101 1e5,128
*Some patient data missing for these variables. ATAQZ Asthma Therapy Assessment Questionnaire; BMIZ body mass index; CIZ
confidence interval; COPDZ chronic obstructive pulmonary disease; FEV1Z forced expiratory volume in 1 s; FVCZ forced vital
capacity; GINAZ Global Initiative for Asthma; NAEPPZ National Asthma Education and Prevention Program; NSZ not significant.
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At the 12-month follow-up, the groups differed on ATAQ,
MiniAQLQ, and WPAI-AS scores; mean post-bronchodilator
FEV1/FVC; and steroid bursts and ER visits (Table 3). The5 lb
(2.27 kg) gain group had the highest impairment scores and
the lowestQoL scores, and they reported the greatest number
of control problems and steroid bursts. The 5 lb (2.27 kg)
loss group reported the greatest number of ER visits.
Asthma control
Patients who gained 5 lb (2.27 kg) between baseline and
follow-up reported poorer asthma control than patients
who maintained their baseline weight or lost 5 lb
(2.27 kg) (unadjusted odds ratio [OR]: 1.36; 95% confi-
dence interval [CI]: 1.14e1.61; pZ 0.0005). The associa-
tion was maintained when baseline BMI, age, gender, race,
treatment specialist, oral steroid use, employment status,
presence of bronchitis, history of allergic rhinitis, and GINA
asthma severity were included in the model (adjusted OR:
1.22; 95% CI: 1.01e1.49; pZ 0.04) (Fig. 3). Baseline BMIFigure 2 Baseline measures of patient body weight (A) and BMI (
follow-up. BMIZ body mass index.and age; being female; being black rather than white; and
being disabled rather than employed full-time were inde-
pendently associated with poor control (all p < 0.05). Poor
control was also independently associated with being
treated by a pulmonologist rather than an allergist; having
a GINA assessment of severe, rather than mild, asthma;
having a history of allergic rhinitis; having bronchitis; and
using oral steroids (all p < 0.05).
Quality of life
Weight gain and loss were associated with asthma-related
QoL, as assessed with the MiniAQLQ (least square [LS]
means: 0.24; 95% CI: 0.36 to 0.11; pZ 0.0003; and LS
means: 0.14; 95% CI: 0.28e0.01; pZ 0.03, respec-
tively). However, after adjusting for baseline BMI and age,
gender, race, education, estimated income, employment
status, health care provider, oral steroid use, bronchitis,
atopic dermatitis, treatment specialist, and asthma
severity, only weight gain was associated with asthma-
related QoL (LS means: 0.18; 95% CI: 0.30 to 0.06;
pZ 0.003) (Fig. 3).C) and changes in body weight (B) and BMI (D) at the 12-month
Table 3 Outcome measures at 12-month follow-up.
Variables Weight change at 12-month follow-up p value
5 lb (2.27 kg) loss Stable 5 lb (2.27 kg) gain
Total patients, n (%) 557 (23.2) 1187 (49.5) 652 (27.2)
Mean post-bronchodilator % predicted FEV1  SD 80.2  21.7 78.7  22.1 79.1  22.9 NS
Mean post-bronchodilator
actual FEV1/FVC (%)  SD
72.8  12.0 71.2  12.3 72.1  11.8 0.046
Mean race-adjusted % predicted FEV1  SD 78.7  21.3 76.2  20.3 76.7  20.9 NS
Overall MiniAQLQ score, mean  SD 5.0  1.4 5.1  1.3 4.9  1.4 0.001
ATAQ control problems, n (%)
0 180 (32.3) 399 (33.6) 193 (29.6) 0.009
1 125 (22.4) 295 (24.9) 134 (20.6)
2 146 (26.2) 304 (25.6) 176 (27.0)
3þ 106 (19.0) 189 (15.9) 149 (22.9)
WPAI-Asthma % overall work impairment,
mean  SD
16.9  23.7 13.1  20.6 19.4  27.2 <0.0001
WPAI-Asthma % overall activity impairment,
mean  SD
26.1  27.6 23.8  26.7 29.0  28.6 0.001
Overnight hospitalization in previous
3 months, n (%)
Yes *18 (3.2) *31 (2.6) *19 (2.9) NS
No 538 (96.8) 1150 (97.4) 631 (97.1)
ER visit in previous 3 months, n (%)
Yes *62 (11.2) *73 (6.2) *56 (8.6) 0.001
No 494 (88.8) 1108 (93.8) 594 (91.4)
Unscheduled office visit in previous
3 months, n (%)
Yes *156 (28.1) *326 (27.6) *205 (31.5) NS
No 400 (71.9) 855 (72.4) 445 (68.5)
Steroid burst in previous
3 months, n (%)
Yes *173 (31.2) *354 (30.0) *234 (36.3) 0.020
No 382 (68.8) 827 (70.0) 411 (63.7)
*Some patient data missing. ATAQZ Asthma Therapy Assessment Questionnaire; ERZ emergency room; FEV1Z forced expiratory
volume in 1 s; FVCZ forced vital capacity; MiniAQLQZ Mini-Asthma Quality of Life Questionnaire; NSZ not significant; WPAI-
AsthmaZ Asthma-Specific Work Productivity and Activity Impairment.
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Weight gain and loss were associated with exacerbations
(unadjusted OR: 1.52; 95% CI: 1.07e2.15; pZ 0.02; OR:
1.87; CI: 1.32e2.65; pZ 0.0004). However, when adjusted
for baseline BMI, age, gender, race, health care provider,
bronchitis, oral steroid use, and race-adjusted percent
predicted FEV1, associations were not maintained (Fig. 3).
Age at baseline; being female; being black rather than
white; using oral steroids; using Medicaid or Medicare
rather than a preferred provider organization; having
bronchitis; and race-adjusted percent predicted FEV1
were independently associated with exacerbations (all
p < 0.05).
Steroid bursts
Patients in the 5 lb (2.27 kg) gain group were more likely
to have experienced steroid bursts during the 3 months
prior to follow-up (OR: 1.33; CI: 1.09e1.63; pZ 0.006).
That relationship was maintained when adjusted forbaseline BMI and age, gender, race, a history of allergic
rhinitis, oral steroid use, skin test, treating specialist,
asthma severity assessed by GINA, and race-adjusted
percent predicted FEV1 (OR: 1.31; CI: 1.04e1.66; pZ 0.02)
(Fig. 3). Age at baseline; using oral steroids at baseline;
having had a negative skin test vs. not having had a skin
test; being treated by a pulmonologist rather than an
allergist; and race-adjusted percent predicted FEV1 were
independently associated with steroid bursts (p < 0.05).
Discussion
Patients with severe or difficult-to-treat asthma who
gained 5 lb (2.27 kg) between baseline and follow-up
reported poorer asthma control, worse QoL, and a greater
number of steroid bursts than patients who maintained
their baseline weight or lost 5 lb (2.27 kg). Although the
magnitude of differences between groups tended to be
small, the findings are consistent with reports that
increases in BMI are associated with decreased asthma
control and asthma-related QoL.24e26
95% CI
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Figure 3 Multivariable regression results assessing the risk of poor asthma control, exacerbations, steroid bursts, and overall
quality of life in patients who gained 5 lb (2.27 kg) vs. those whose weight remained stable, and in patients who lost 5 lb
(2.27 kg) vs. those whose weight remained stable.
Weight change and asthma-related health outcomes 281The association between BMI and asthma is widely
recognized (for references and review see Chinn4 and
Ford1). However, in many studies it is not clear if increased
BMI precedes asthma onset or if it results from physical and
physiological restrictions imposed by asthma. In the present
study, changes in body weight/BMI preceded ATAQ and
MiniAQLQ evaluations. The finding that patients who gained
5 lb (2.27 kg) had a greater number of control problems,
lower QoL, and more steroid bursts at follow-up suggests
that weight gain affected those outcomes rather than vice
versa.27e30 Although a 5 lb (2.27 kg) weight change
resulted in a 0.23 change in the AQLQ and did not constitute
a meaningful difference, if we assume linearity and an MID
of 0.5, an 11 lb (5 kg) weight change would correspond to
a meaningful change in QoL.
Gender differences in weight gain and asthma control
were not specifically evaluated. The literature pertaining
to gender differences in the BMI-asthma relationship isinconsistent; some studies report no gender differ-
ences.30,31 Others suggest that the relationship is stronger
in women29,32,33 or that in men asthma is associated with
both high and low BMI34 or based on an interaction of
gender and race.35 In our study, the relationship between
weight gain and poor asthma control was maintained when
the model was adjusted for gender, indicating that gender
did not modify the BMI-control relationship. One possible
reason that gender effects were not apparent in our study is
that our analysis was limited to patients with severe or
difficult-to-treat asthma. Weight gain may have a greater
effect on men with severe or difficult-to-treat asthma than
on men with mild or moderate asthma.
Patients who gained 5 lb (2.27 kg) reported a greater
number of steroid bursts than those who lost or maintained
their weight. Weight gain is an often-reported side effect of
oral corticosteroids. However, in a previous study of
z18,000 asthma patients, oral corticosteroid use did not
282 T. Haselkorn et al.contribute to obesity.36 In the present study, percent corti-
costeroid use at baseline was, in fact, lower in patients who
gained 5 lb (2.27 kg) compared to those who lost weight
or remained stable. Despite reporting lower corticosteroid
use at baseline, patients who gained 5 lb (2.27 kg) had
a greater number of steroid bursts at 12-month follow-up.
Such data suggest that weight gain may predispose patients
to being more symptomatic or increase the severity of
existing symptoms, thereby necessitating steroid bursts.
To date, relatively few studies have examined weight
loss in relation to asthma outcomes37 and the majority have
involved interventions. In these studies, such as the Stenius-
Aarniala et al. study38 which included a supervised weight
reduction program over an 8 week period, improvements in
at least one asthma-related health outcome were observed.
Our study did not identify improved outcomes with weight
loss. However, TENOR, by design, was a naturalistic study
conducted over a 3-year period. Thus, weight gain and loss
was random and at the discretion (purposeful or not) of the
patient. In addition, mean weight loss in randomized
controlled trials, such as the Stenius-Aarniala et al. study
(14.2 kg), was much higher than in the TENOR study.
As stated earlier, the 5 lb (2.27 kg) cutpoint was chosen
for assessing weight gain/loss because changes of that
magnitude were sufficiently common in our cohort to allow
for comparisons, but not likely to be visit-to-visit
measurement error. In fact, we conducted an analysis using
the original 5 lb cutoff, in addition to other thresholds,
including 10 lb (4.5 kg), 15 lb (6.8 kg), and 1 standard
deviation of the weight difference (11.6 lbs (5.3 kg)). We
found that the estimated odds ratios for the ATAQ, exac-
erbation, and steroid burst outcomes and the least square
means for the quality of life outcomes were similar,
regardless of the threshold used. However, we lost a fair
amount of statistical power at the higher thresholds
because confidence bounds became wider due to the
stricter definition of weight gain (fewer patients lose
greater amounts of weight). This is one of the reasons why
we chose the 5 lb cutoff; it was the largest weight cutoff we
could use while making estimates of the effects with
reasonable precision. In addition, 5 lb was deemed to be
a low, yet reasonable and actionable cutpoint that physi-
cians could easily communicate to their patients.
This study had several limitations. First, due to the un-
randomized nature of the study, we cannot be certain of
a direct causal relationship between weight gain and poor
asthma outcomes. Second, asthma control differed
between weight groups at baseline. To account for these
differences and the possible influence of asthma control on
steroid use, a sensitivity analysis in which baseline control
was added did not substantially change the results. Third,
the outcome measures were based on self-assessments and
reports, which were influenced by patients’ memory and
other psychosocial factors. There is evidence that obese
asthma patients tend to rate their symptoms more severely
than non-obese patients, although both groups experience
similar exacerbations.39 Finally, no measures of body
weight distribution or comorbidities associated with
weight, such as sleep apnea, were collected in TENOR and
thus could not be examined in relation to our findings.
It is clear from our results and those of others28,30,40 that
the relationship between BMI and asthma is complex, andinteractions of many demographic and clinical variables
determine asthma control. Hence, the goal of future
studies should be to more closely examine variables that
contribute to poor asthma control and determine the
threshold at which BMI affects the severity and control of
asthma and/or interacts with other variables to affect
asthma severity and control.
In conclusion, strategies to prevent weight gain could
help patients achieve better asthma control and improve
asthma-related QoL. A clearer understanding of the
mechanisms by which body weight/BMI influences asthma
control and other asthma-related outcomes will enable
treatment specialists to formulate treatment programs that
include a weight-management component.
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